...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines.
【24h】

Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines.

机译:组胺和过敏原引起的皮肤反应的抑制:第一代和第二代抗组胺药的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Nonsedating antihistamines (nsAHs) are recommended as first-line therapeutics for the treatment of mast cell-driven disorders, including allergic rhinitis and urticaria. However, their superiority over first-generation AHs (fgAHs) has recently been called into question, mainly because of the lack of supporting head-to-head therapeutic studies. OBJECTIVE: To compare the effects of 3 modem nsAHs with those of the fgAH hydroxyzine on histamine- and allergen-induced skin reactions in a controlled, double-blind, clinical trial. METHODS: Skin prick tests with histamine and Dermatophagoides pteronyssinus extract were performed before and 4 hours after treatment with hydroxyzine, 25 mg; desloratadine, 5 mg; epinastine, 20 mg; fexofenadine, 120 mg; or placebo. Wheal and erythema development was evaluated by digital photography and planimetric analyses. RESULTS: The nsAHs prevented the development of positive reactions to histamine in only 10% to 20% of all individuals tested (n = 75). In contrast, more than 50% of all hydroxyzine-treated individuals showed negative test reactions to histamine (ie, wheals <7 mm2 in area or <3 mm in diameter). Similar differences, although less pronounced, were detected when comparing the effects of nsAHs with hydroxyzine on D pteronyssinus prick testing in a limited number of D pteronyssinus-sensitized individuals. CONCLUSIONS: These results indicate that hydroxyzine is more effective than nsAHs when given as recommended in suppressing histamine-induced or allergic skin reactions. Our results suggest that higher doses of nsAHs than those currently recommended are required for the treatment of skin responses to obtain antihistaminic and antiallergic effects that are equivalent to those of fgAHs.
机译:背景:非镇静抗组胺药(nsAHs)被推荐作为治疗肥大细胞驱动疾病(包括变应性鼻炎和荨麻疹)的一线治疗剂。但是,最近它们比第一代AHs(fgAHs)的优势受到质疑,主要是因为缺乏支持的头对头治疗研究。目的:在一项受控的双盲临床试验中,比较3种现代nsAH和fgAH羟嗪对组胺和过敏原引起的皮肤反应的影响。方法:在25 mg羟嗪治疗之前和之后4小时,用组胺和Dermatophagoides pteronyssinus提取物进行皮肤点刺试验。地氯雷他定5 mg;癫痫药20毫克;非索非那定,120毫克;或安慰剂。通过数字摄影和平面分析评估了鲸鱼和红斑的发展。结果:nsAHs仅在所有测试个体中阻止了对组胺的阳性反应的发展(n = 75)。相反,在所有接受羟嗪治疗的个体中,有超过50%的人对组胺表现出阴性测试反应(即,风团的面积<7 mm2或直径<3 mm)。当比较nsAHs和羟嗪对有限数量的D蕨类植物敏化个体中D蕨类植物点刺试验的效果时,发现了相似的差异,尽管不太明显。结论:这些结果表明,按推荐的剂量服用羟嗪抑制组胺引起的或过敏性皮肤反应比nsAHs更有效。我们的结果表明,要获得与fgAHs等效的抗组胺和抗过敏作用,需要比目前推荐的剂量更高的nsAHs剂量才能治疗皮肤反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号